Update on diabetes management- Omarigliptin: The new kid in the basket

Abstract

The landscape of diabetes management continues to evolve, with ongoing efforts to enhance treatment options and improve patient outcomes. In this pursuit, a promising addition has emerged in Bangladesh – Omarigliptin which sheds light on the latest updates in diabetes management. Omarigliptin, a novel once-weekly DPP-4 inhibitor, has gained attention for its efficacy and unique dosing regimen. The approval of Omarigliptin by the Japanese PMDA was based on a comprehensive Phase 3 global clinical trial O-QWEST with over 8,000 patients. Its rapid absorption, coupled with a prolonged half-life, supports its weekly dosing schedule. Moreover, the dose-dependent improvements observed in key pharmacokinetic parameters underline its efficacy in HbA1c, 2hr-PPG, and FPG levels management and were found non-inferior to other DPP-4 inhibitors like sitagliptin & linagliptin. Additionally, the cardiovascular safety profile of Omarigliptin, as demonstrated by its non-inferiority to existing treatments and absence of increased risks, positions it as a valuable option for patients with cardiovascular concerns. Beyond glycemic control, studies suggest its potential to ameliorate hepatic insulin resistance and confer anti-inflammatory effects, thus extending its impact beyond glucose regulation. Moreover, Omarigliptin might have benefits for patients with non-alcoholic fatty liver disease- NAFLD or NASH.

In the realm of diabetes management, where treatment adherence plays a pivotal role, Omarigliptin offers a novel advantage with its once-weekly dosing. Its distinct pharmacokinetic profile, cardiovascular benefits, and potential for broader metabolic impacts contribute to its significance in the diabetes treatment landscape

Keywords: Omarigliptin, Type 2 diabetes, DPP4 inhibitor